Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis

被引：0
|
作者：
Kappos, L.
Leppert, D.
Tinbergen, J.
Gerber, M.
Hauser, S. L.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [41] Anti-CD20 monoclonal antibodies: reviewing a revolution
    Casan, J. M. L.
    Wong, J.
    Northcott, M. J.
    Opat, S.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (12) : 2820 - 2841
  • [42] Mechanisms of killing by anti-CD20 monoclonal antibodies
    Glennie, Martin J.
    French, Ruth R.
    Cragg, Mark S.
    Taylor, Ronald P.
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3823 - 3837
  • [43] Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) : 444 - 449
  • [44] Idiopathic systemic vasculitis (IVS) remission after treatment with anti-CD20 monoclonal antibodies
    Roccatello, D.
    Rossi, D.
    Baldovino, S.
    Alpa, M.
    Naretto, C.
    Brosio, P.
    Napoli, F.
    La Grotta, R.
    Cavallo, R.
    Giachino, O.
    Sena, L. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 382 - 383
  • [45] Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab
    Focosi, Daniele
    Tuccori, Marco
    Maggi, Fabrizio
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2019, 29 (06)
  • [46] Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis
    Wollina, Uwe
    [J]. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 2010, 4 (03): : 44 - 46
  • [47] CHARACTERIZATION OF A PATIENTS' ANTIBODIES TO THE ANTI-CD20 THERAPEUTIC RITUXIMAB
    Mahadik, Younis
    Young, Stephen
    Morgan, Matthew
    Gordon, Caroline
    Harper, Lorraine
    [J]. RHEUMATOLOGY, 2012, 51 : 142 - 143
  • [48] Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies
    Gasperini, Claudio
    Haggiag, Shalom
    Ruggieri, Serena
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (10) : 1243 - 1253
  • [49] Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
    Ng, CM
    Bruno, R
    Combs, D
    Davies, B
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07): : 792 - 801
  • [50] Optimizing the Use of Rituximab and Other Anti-CD20 Antibodies
    Richards, Kristy L.
    [J]. ONCOLOGIST, 2012, 17 : 8 - 8
12345